ImmunityBio Director Simon Barry J. Sells $165,305 in Stock
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
immunitybioinsider-trading
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
On June 5, 2026, a regulatory filing disclosed that ImmunityBio, Inc. director Simon Barry J. sold a total of $165,305 worth of the company's common stock. The transaction was executed over multiple trades at prices ranging from $5.50 to $5.63 per share. This sale reduced Barry's direct holdings in the clinical-stage immunotherapy company. The filing was publicly disseminated after market hours.
Insider selling at biotechnology firms is closely monitored for shifts in sentiment, particularly following significant clinical or regulatory milestones. ImmunityBio is developing therapies for cancer and infectious diseases, with its lead asset, Anktiva, receiving FDA approval for BCG-unresponsive non-muscle invasive bladder cancer in April 2023. The company's stock has experienced substantial volatility since that approval, rising over 200% in the subsequent six months before retracing most of those gains. Director Barry's sale occurs as the broader biotech sector, tracked by the SPDR S&P Biotech ETF (XBI), faces pressure from sustained higher interest rates, which increase the cost of capital for pre-revenue companies. The current 10-year Treasury yield is 4.31%, a level that typically compresses valuations for long-duration assets like developmental-stage biotechs. The immediate catalyst for this specific transaction appears to be a recent stock price rebound of approximately 15% from its May 2026 lows, providing a window for liquidation.
The transaction involved the sale of 29,600 shares at a weighted average price of $5.59. This sale reduced Simon Barry J.'s direct holdings in ImmunityBio. The total value of $165,305 represents a minor fraction of the company's market capitalization, which stands near $4.1 billion. ImmunityBio's stock price closed at $5.62 on the day of the filing, down 2.3% for the session. The stock's performance contrasts with the NASDAQ Biotechnology Index (NBI), which is down 5% year-to-date. Trading volume for ImmunityBio was 1.8 million shares on June 5, slightly above its 30-day average of 1.5 million. The table below shows the director's recent trading activity.
| Date | Transaction Type | Shares | Price Range | Total Value |
|---|---|---|---|---|
| 05 Jun 2026 | Sale | 29,600 | $5.50 - $5.63 | $165,305 |
ImmunityBio reported a net loss of $180.4 million for the first quarter of 2026, compared to a $183.7 million loss in the prior-year period.
A director's sale at a clinical-stage company often invites scrutiny, but the modest size of this transaction suggests routine portfolio management rather than a signal of eroding confidence. The liquidity event is unlikely to directly impact ImmunityBio's cash position or operational runway. The broader implication for the biotech sector (XBI) is neutral, as single insider sales are common and rarely move sector-wide valuations. However, sustained or concentrated insider selling across multiple executives at similar companies like Nkarta, Inc. (NKTX) or Iovance Biotherapeutics (IOVA) could signal a sector-wide reassessment of valuation peaks. A key counter-argument is that directors frequently sell shares for personal financial planning reasons unrelated to company prospects, such as tax obligations or diversification. Trading flow data indicates that institutional ownership of ImmunityBio has remained stable over the past quarter, with no mass exodus following the filing. Hedge fund positioning in high-beta biotech names remains cautious, with net short interest elevated relative to the S&P 500.
Markets will monitor ImmunityBio's second-quarter 2026 earnings report, expected in early August, for updates on Anktiva's commercial rollout and trial progress for other indications. Key clinical catalysts to watch include data readouts from the company's pancreatic cancer and glioblastoma studies, anticipated in the fourth quarter of 2026. From a technical analysis perspective, the stock's 50-day moving average at $5.40 serves as near-term support, with resistance established at the June high of $6.10. A break above $6.25 on heavy volume could indicate a reversal of the prevailing downtrend. The next significant market-wide event for biotech will be the Fed's policy decision on June 18, 2026, as interest rate guidance directly influences capital allocation to the sector. If inflation data remains sticky, prompting a more hawkish Fed stance, biotech ETFs like XBI could test their 52-week lows.
An insider sale is one data point among many and rarely a sole reason for action. Retail investors should assess the sale's context, including its size relative to the executive's total holdings and whether it is part of a planned trading schedule. For ImmunityBio, the $165,305 sale is small relative to the company's multi-billion dollar market cap and daily trading volume. It is more informative to track trends, such as multiple insiders selling simultaneously or sales occurring immediately before negative news.
Over the past 12 months, insider activity at ImmunityBio has been mixed, featuring both acquisitions and dispositions. Executive Chairman Dr. Patrick Soon-Shiong has made several open-market purchases, adding to his substantial position. This pattern of buying by a key founder alongside selling by a non-executive director is not uncommon and reflects different investment horizons and personal liquidity needs rather than a unified insider view.
Academic studies show a weak correlation between isolated insider sales and subsequent long-term stock underperformance in the volatile biotech sector. Stock price movement is far more dependent on clinical trial results, regulatory decisions, and partnership announcements. For example, a director's sale at Moderna in 2019 preceded a multi-year rally driven by its COVID-19 vaccine success, demonstrating that fundamental catalysts overwhelmingly outweigh insider trading signals.
The sale is a minor liquidity event unlikely to alter ImmunityBio's financial or clinical trajectory.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
